Biology Reference
In-Depth Information
16.
Lymperopoulos A, Rengo G, Gao E, Ebert SN, Dorn 2nd GW, Koch WJ. Reduction
of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart fail-
ure progression and improves cardiac function after myocardial infarction.
J Biol Chem
.
2010;285:16378
-
16386.
17.
Lymperopoulos A, Rengo G, Zincarelli C, Soltys S, Koch WJ. Modulation of adrenal
catecholamine secretion by in vivo gene transfer and manipulation of G protein-
coupled receptor kinase-2 activity.
Mol Ther
. 2008;16:302-
307.
18.
Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-
tuning cardiac stimulation.
Trends Mol Med
. 2007;13:503
-
511.
19.
Wang Q, Zhao J, Brady AE, et al. Spinophilin blocks arrestin actions in vitro and
in vivo at G protein-coupled receptors.
Science
. 2004;304:1940-
1944.
20.
Schmid CL, Bohn LM. Physiological and pharmacological implications of beta-arrestin
regulation.
Pharmacol Ther
. 2009;121:285-
293.
21.
Rengo G, Lymperopoulos A, Koch WJ. Future G protein-coupled receptor targets for
treatment of heart failure.
Curr Treat Options Cardiovasc Med
. 2009;11:328-
338.
22.
Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adeno-associated virus
serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neu-
rohormonal axis in chronic heart failure.
Circulation
. 2009;119:89
-
98.
23.
Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy tar-
get in heart failure.
J Mol Cell Cardiol
. 2011;50:785-
792.
24.
Lymperopoulos A, Rengo G, Koch WJ. GRK2 inhibition in heart failure: something
old, something new.
Curr Pharm Des
. 2012;18:186
-
191.
25.
Noma T, Lemaire A, Naga Prasad SV, et al. Beta-arrestin-mediated beta1-adrenergic
receptor
transactivation of
the EGFR confers cardioprotection.
J Clin Invest
.
2007;117:2445-
2458.
26.
Tilley DG. G protein-dependent and G protein-independent signaling pathways and
their impact on cardiac function.
Circ Res
. 2011;109:217-
230.
27.
Noor N, Patel CB, Rockman HA.
b
-arrestin: a signaling molecule and potential ther-
apeutic target for heart failure.
J Mol Cell Cardiol
. 2011;51:534-
541.
28.
Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular
signal-regulated kinases by beta-arrestin scaffolds.
Proc Natl Acad Sci USA
.
2001;98:2449-
2454.
29.
Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. Beta-arrestin inhibits
NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor
IkappaBalpha.
Proc Natl Acad Sci USA
. 2004;101:8603-
8607.
30.
Gao H, Sun Y, Wu Y, et al. Identification of beta-arrestin2 as a G protein-coupled
receptor-stimulated regulator of NF-kappaB pathways.
Mol Cell
. 2004;14:303-
317.
31.
Zhai P, Yamamoto M, Galeotti J, et al. Cardiac-specific overexpression of AT1 recep-
tor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in
transgenic mice.
J Clin Invest
. 2005;115:3045
-
3056.
32.
Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated
kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct pheno-
types of cardiac myocytes.
Basic Clin Pharmacol Toxicol
. 2007;100:296-
301.
33.
Rajagopal K, Whalen EJ, Violin JD, et al. Beta-arrestin2-mediated inotropic effects of
the angiotensin II type 1A receptor in isolated cardiac myocytes.
Proc Natl Acad Sci USA
.
2006;103:16284
-
16289.
34.
Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. Beta-arrestin-biased
agonism of the angiotensin receptor induced by mechanical stress.
Sci Signal
. 2010;3:
ra46.
35.
Kim J, Zhang L, Peppel K, et al. Beta-arrestins regulate atherosclerosis and neointimal
hyperplasia by controlling smooth muscle cell proliferation and migration.
Circ Res
.
2008;103:70-
79.
Previous Page
Next Page
Progress in Molecular Biology and Translational Science
Search WWH ::
Custom Search
Home